Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine

References

• Taquet M, Luciano S, Geddes JR, et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA. Lancet Psychiatry. 2021 Feb;8(2):130–140.
   PubMed Web of Science ®Google Scholar
• Czeisler M, Wiley JF, Facer-Childs ER, et al. Mental health, substance use, and suicidal ideation during a prolonged COVID-19-related lockdown in a region with low SARS-CoV-2 prevalence. J Psychiatr Res. 2021 Aug;140:533–544.
   PubMed Web of Science ®Google Scholar
• Farooq S, Tunmore J, Wajid Ali M, et al. Suicide, self-harm and suicidal ideation during COVID-19: a systematic review. Psychiatry Res. 2021 Dec;306:114228.
   PubMed Web of Science ®Google Scholar
• Averill LA, Fouda S, Murrough JW, et al. Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: an abridged review of the clinical evidence. Adv Pharmacol. 2020;89:163–194.
   PubMedGoogle Scholar
• Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006 Jan 25;2006(1):Cd002795.
   Google Scholar
• Ipser J, Seedat S, Stein DJ. Pharmacotherapy for post-traumatic stress disorder - a systematic review and meta-analysis. S Afr Med J. 2006 Oct;96(10):1088–1096.
   PubMed Web of Science ®Google Scholar
• Friedman MJ, Marmar CR, Baker DG, et al. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007 May;68(5):711–720.
   PubMed Web of Science ®Google Scholar
• Hoskins MD, Bridges J, Sinnerton R, et al. Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. Eur J Psychotraumatol. 2021;12(1):1802920.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Mamdani MM, Kopp A, et al. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry. 2006 May;163(5):813–821.
   PubMed Web of Science ®Google Scholar
• Schnurr PP, Chard KM, Ruzek JI, et al. Comparison of Prolonged Exposure vs Cognitive Processing Therapy for Treatment of Posttraumatic Stress Disorder Among US Veterans: a Randomized Clinical Trial. JAMA Network Open. 2022 Jan 4;5(1):e2136921.
   PubMed Web of Science ®Google Scholar
• Krediet E, Bostoen T, Breeksema J, et al. Reviewing the Potential of Psychedelics for the Treatment of PTSD. Int J Neuropsychopharmacol. 2020 Jun 24;23(6):385–400.
   PubMed Web of Science ®Google Scholar
• Olson DE. Psychoplastogens: a Promising Class of Plasticity-Promoting Neurotherapeutics. J Exp Neurosci. 2018;12:1179069518800508.
   Web of Science ®Google Scholar
• Krystal JH, Abdallah CG, Averill LA, et al. Synaptic Loss and the Pathophysiology of PTSD: implications for Ketamine as a Prototype Novel Therapeutic. Curr Psychiatry Rep. 2017 Aug 26;19(10):74.
   PubMed Web of Science ®Google Scholar
• Savalia NK, Shao LX, Kwan AC. A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics. Trends Neurosci. 2021 Apr;44(4):260–275.
   PubMed Web of Science ®Google Scholar
• Shao LX, Liao C, Gregg I, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021 Aug 18;109(16):2535–2544.e4.
   PubMed Web of Science ®Google Scholar
• Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018 June 12;23(11):3170–3182.
   PubMed Web of Science ®Google Scholar
• Nardou R, Lewis EM, Rothhaas R, et al. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature. 2019 May;569(7754):116–120.
   PubMed Web of Science ®Google Scholar
• Abad S, Camarasa J, Pubill D, et al. Adaptive Plasticity in the Hippocampus of Young Mice Intermittently Exposed to MDMA Could Be the Origin of Memory Deficits. Mol Neurobiol. 2016 Dec;53(10):7271–7283.
   PubMed Web of Science ®Google Scholar
• Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021 Jun;27(6):1025–1033.
   PubMed Web of Science ®Google Scholar
• Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. 2020 May 1;177(5):391–410.
   PubMed Web of Science ®Google Scholar
• Nutt D. Psychedelic drugs-a new era in
psychiatry?. Dialogues Clin Neurosci. 2019;21(2):139–147.
   PubMed Web of Science ®Google Scholar
• Varker T, Watson L, Gibson K, et al. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: a Systematic Review of MDMA, Ketamine, LSD and Psilocybin. J Psychoactive Drugs. 2021 Jan-Mar;53(1):85–95.
   PubMed Web of Science ®Google Scholar
• Sessa B. MDMA and PTSD treatment: “PTSD: from novel pathophysiology to innovative therapeutics. Neurosci Lett. 2017 May 10;649:176–180
   PubMed Web of Science ®Google Scholar
• Abdallah CG, Roache JD, Gueorguieva R, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;19:1–8.
   Google Scholar
• Vermetten E, Krediet E, Bostoen T, et al. Psychedelics in the treatment of PTSD. Tijdschr Psychiatr. 2020;62(8):640–649.
   PubMedGoogle Scholar
• Feder A, Costi S, Rutter SB, et al. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021 Feb 1;178(2):193–202.
   PubMed Web of Science ®Google Scholar
• Feder A, Rutter SB, Schiller D, et al. The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Adv Pharmacol. 2020;89:261–286.
   PubMedGoogle Scholar
• Latimer D, Stocker MD, Sayers K, et al. MDMA to Treat PTSD in Adults. Psychopharmacol Bull. 2021 Jun 1;51(3):125–149.
   PubMedGoogle Scholar
• Davis AK, Averill LA, Sepeda ND, et al. Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. Chronic Stress (Thousand Oaks). Chronic Stress (Thousand Oaks, Calif.). 2020 Jan-Dec;4:2470547020939564.
   Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351–354.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856–864.
   PubMed Web of Science ®Google Scholar
• Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012 Oct 5;338(6103):68–72.
   PubMed Web of Science ®Google Scholar
• Smigielski L, Scheidegger M, Kometer M, et al. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage. 2019 Aug 1;196:207–215.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017 Oct 13;7(1):13187.
   PubMedGoogle Scholar
• Barrett FS, Krimmel SR, Griffiths RR, et al. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. Neuroimage. 2020 Sep;218:116980.
   PubMed Web of Science ®Google Scholar
• Phelps J, Shah RN, Lieberman JA. The Rapid Rise in Investment in Psychedelics-Cart Before the Horse. JAMA Psychiatry. 2022 Jan 19; https://doi.org/10.1001/jamapsychiatry.2021.3972.
   Google Scholar
• Noorani T, Martell J. New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy. Front Psychiatry. 2021;12:727050.
   PubMedGoogle Scholar
• Thrul J, Garcia-Romeu A. Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment. Drugs: Education, Prevention and Policy. 2021 May 04;28(3):211–214.
   Web of Science ®Google Scholar
• Williams MT, Davis AK, Xin Y, et al. People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs (Abingdon Engl). 2021;28(3):215–226.
   PubMedGoogle Scholar
• Smith DT, Faber SC, and Buchanan NT, et al. The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision [Hypothesis and Theory]. Front Psychiatry. 2022 January 20;12:774736. doi: https://doi.org/10.3389/fpsyt.2021.774736. eCollection 2021.
   Google Scholar
• Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021 Sep;14(9):1133–1152.
   PubMed Web of Science ®Google Scholar
• Schenberg EE. Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021 Oct 03;14(10):1317–1319.
   PubMed Web of Science ®Google Scholar
• Hesselgrave N, Troppoli TA, Wulff AB, et al. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):e2022489118.
   PubMed Web of Science ®Google Scholar
• Yaden DB, Griffiths RR. The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol Transl Sci. 2021 Apr 09;4(2):568–572.
   PubMedGoogle Scholar
• Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7(3):157–164.
   PubMedGoogle Scholar
• Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006 Aug;1873:268–283. discussion 284-92.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011 Dec;218(4):649–665.
   PubMed Web of Science ®Google Scholar
• Valuck RJ, Orton HD, Libby AM. Antidepressant discontinuation and risk of suicide attempt: a retrospective, nested case-control study. J Clin Psychiatry. 2009 Aug;70(8):1069–1077.
   PubMed Web of Science ®Google Scholar
• Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol. 2008 May;22(3):330–332.
   PubMed Web of Science ®Google Scholar
• Zeifman RJ, Yu D, Singhal N, et al. Decreases in Suicidality Following Psychedelic Therapy: a Meta-Analysis of Individual Patient Data Across Clinical Trials. J Clin Psychiatry. 2022 Jan 18;83(2): https://doi.org/10.4088/JCP.21r14057.
   Google Scholar
• Hendricks PS, Thorne CB, Clark CB, et al. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015 Mar;29(3):280–288.
   PubMed Web of Science ®Google Scholar
• Vann Jones SA, O’Kelly A. Psychedelics as a Treatment for Alzheimer’s Disease Dementia. Front Synaptic Neurosci. 2020;12:34.
   PubMed Web of Science ®Google Scholar
• Kozlowska U, Nichols C, Wiatr K, et al. From psychiatry to neurology: psychedelics as prospective therapeutics for neurodegenerative disorders. J Neurochem. 2021 Sep 13; https://doi.org/10.1111/jnc.15509.
   Google Scholar